The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis. Materials and Methods: Multicentre, randomized, open-label, non-inferiority trial (non-inferiority margin (10%). Treatment failure (TF) was defined as CVF (two consecutive HIV-RNA 50 cp/mL) or discontinuation for any cause. In the monotherapy arm, patients with CVF re-introduced their previous NRTIs and remained in the study if HIV-RNA B50 copies/mL within 12 weeks of re-intensification. Results: 101 patients evaluated (Figure 1 ): 85% males, 21% HCV-positive, median (IQR) age of 42 (36Á48) years, baseline CD4' 576 (447Á743) cells/mL. In the 96-week analysis (ITT; TF 0failure), efficacy was 64% (32/50) in the monotherapy arm and 63% (32/51) in the triple-therapy arm (difference '1.3%, 95% CI (17.5Á20.1). Fourteen patients in monotherapy and two in tripletherapy arm had CVF; median HIV-RNA was 136 (72Á376) copies/mL. In monotherapy arm, no PI or NRTI associated resistance mutations were observed at CVF. All patients who re-intensified re-suppressed. In monotherapy arm, TF was more frequent in HCV-co-infected patients (64% vs 28%; p00.041). In the secondary analysis (ITT; re-intensification 0success), 82% (41/50) in monotherapy arm and 63% (32/51) in triple-therapy arm were on study at week 96 (difference '19.3%, 95% CI 2.2Á36.3). SAEs occurred in four (8%) patients in the monotherapy arm (one left basal pneumonia, one acute coronary stenosis, one traumatic lesion, one nephrolithiasis) and two (4%) in the triple therapy arm (one sepsis, one renal failure). Drug-related adverse events (AEs) leading to discontinuation were three (6%) in the monotherapy arm (two AEs occurred in patients after successful reintensification) and 12 (23.5%) in the triple-therapy (p 00.023). Conclusions: Despite the small sample size, the primary 96-week analysis showed that simplification to ATV/r monotherapy showed inferior efficacy to maintaining ATV/r triple-therapy but appeared to be superior when re-intensification was considered success.
Introduction:
The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis. Materials and Methods: Multicentre, randomized, open-label, non-inferiority trial (non-inferiority margin (10%). Treatment failure (TF) was defined as CVF (two consecutive HIV-RNA 50 cp/mL) or discontinuation for any cause. In the monotherapy arm, patients with CVF re-introduced their previous NRTIs and remained in the study if HIV-RNA B50 copies/mL within 12 weeks of re-intensification. Results: 101 patients evaluated ( Figure 1 ): 85% males, 21% HCV-positive, median (IQR) age of 42 (36Á48) years, baseline CD4' 576 (447Á743) cells/mL. In the 96-week analysis (ITT; TF 0failure), efficacy was 64% (32/50) in the monotherapy arm and 63% (32/51) in the triple-therapy arm (difference '1.3%, 95% CI (17.5Á20.1). Fourteen patients in monotherapy and two in tripletherapy arm had CVF; median HIV-RNA was 136 (72Á376) copies/mL. In monotherapy arm, no PI or NRTI associated resistance mutations were observed at CVF. All patients who re-intensified re-suppressed. In monotherapy arm, TF was more frequent in HCV-co-infected patients (64% vs 28%; p00.041). In the secondary analysis (ITT; re-intensification 0success), 82% (41/50) in monotherapy arm and 63% (32/51) in triple-therapy arm were on study at week 96 (difference '19.3%, 95% CI 2.2Á36.3). SAEs occurred in four (8%) patients in the monotherapy arm (one left basal pneumonia, one acute coronary stenosis, one traumatic lesion, one nephrolithiasis) and two (4%) in the triple therapy arm (one sepsis, one renal failure). Drug-related adverse events (AEs) leading to discontinuation were three (6%) in the monotherapy arm (two AEs occurred in patients after successful reintensification) and 12 (23.5%) in the triple-therapy (p 00.023). Conclusions: Despite the small sample size, the primary 96-week analysis showed that simplification to ATV/r monotherapy showed inferior efficacy to maintaining ATV/r triple-therapy but appeared to be superior when re-intensification was considered success. 
